New research suggests that individuals who come off new GLP-1 drugs like semaglutide or tirzepatide tend to recover shed pounds much more quickly than those who halt traditional diet and exercise regimens.
Published data in a prominent health publication demonstrates that while obese people can lose about a fifth of their body weight while undergoing treatment, the mass returns at an average rate of nearly a kilo each month after stopping.
"Individuals using these drugs need to be cognizant of the risk of quick rebound weight gain when the therapy concludes," cautioned researcher Dr. Susan Jebb.
That rate of regain means a reversion to starting weight in about 18 months.
Weighing Treatments
The analysis, which looked at dozens of studies involving thousands of participants, contrasted the results of these new drugs with conventional dieting.
The team point out that people who lose weight through diet and exercise usually experience a slower weight regain—approximately 100 grams monthly—after stopping.
Explaining the Fast Regain
Doctors believe the mode of action of the injections is key to understanding the heightened regain.
The injections mimic a natural hormone called GLP-1, which controls appetite.
"Artificially providing the hormone levels several times higher than the body's typical production could lead to the body to produce less of its own natural GLP-1, and may also reduce sensitivity to its effects," noted Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this GLP-1 'fix' results in appetite is no longer kept in check, making overeating much more probable."
An Ongoing Disease?
Health authorities recommend the injections for individuals with weight-linked medical conditions, accompanied by prescribed lifestyle changes.
A number of clinicians say that, considering the significant potential of weight regain, the therapy is often ongoing.
This perspective is reinforced by pharmaceutical companies, who state that the findings "underscore the chronic character of obesity," similar to managing conditions like diabetes.
Patient Accounts
Individuals who have discontinued the jabs explain a intense return of appetite.
"It was like a trigger flipping and I was suddenly extremely hungry," recalled a patient.
This challenge is exacerbated if individuals have not developed permanent dietary or behavioural modifications during therapy.
Significant Interest
Survey data suggest that a significant number of adults in the UK have tried weight-loss jabs in the past year, with desire remaining high.
- Adoption is higher among women than males.
- The 40s and 50s demographic shows the highest level of interest.
- A large proportion obtain the drugs through private prescriptions rather than public health services.
In conclusion, researchers caution that while the jabs are potent tools for shedding pounds, they are not a magic cure and long-term success relies on integrated lifestyle support.
